Landfar Bio-medicine: The company's stock trading may be subject to delisting risk warning
According to the announcement from Landfar Bio-medicine, the company expects its net profit for the fiscal year 2024 and net profit after deducting non-recurring gains and losses to both be negative, and the operating income after deduction is expected to be below 300 million yuan. According to Article 9.3.1 (1) of the Shenzhen Stock Exchange Stock Listing Rules, after the disclosure of the company's 2024 annual report, the trading of the company's stock may be subject to delisting risk warning (the stock abbreviation will be prefixed with "*ST")
According to the announcement from Zhitong Finance APP, Landfar Bio-medicine (000504.SZ) expects that the company's net profit for the fiscal year 2024, as well as the net profit after deducting non-recurring gains and losses, will both be negative, and the operating revenue after deductions will be less than 300 million yuan. According to Article 9.3.1 (1) of the Shenzhen Stock Exchange's Listing Rules, after the disclosure of the company's 2024 annual report, the trading of the company's stock may be subject to delisting risk warnings (with the stock abbreviation prefixed by "*ST")
